Multiple oral direct-acting antiviral agents show great promise in treating the vast majority of hepatitis C patients.
The introduction of direct-acting antiviral agents has transformed hepatitis C care among veterans.
Early data shows promise in “real-world” effectiveness.
Physicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.
Researchers say theirs is first national study with a large population to examine possible link.
All-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.
A new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant.
Direct-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author.
This slide show highlights the top 10 issues we covered this year on managing treatment of patients with HCV infection.
Patients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.